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Background: Most studies of anti-transglutaminase (an-
ti-tTG) assays have considered preselected groups of
patients. This study compared the sensitivity, specific-
ity, and predictive value of an immunofluorescence
method for anti-endomysial antibodies (EmAs) and two
anti-tTG ELISAs, one using guinea pig tTG (gp-tTG)
and the other human tTG (h-tTG) as antigen, in consec-
utive patients investigated for suspected celiac disease
(CD).
Methods: We studied 207 consecutive patients (99 men,
108 women; age range, 17–84 years) who underwent
intestinal biopsy for suspected CD. Patients presented
with one or more of the following: weight loss, anemia,
chronic diarrhea, abdominal pain, dyspepsia, alternat-
ing bowel habits, constipation, pain in the joints, and
dermatitis. At entry to the study, an intestinal biopsy
was performed and a serum sample was taken for IgA
EmAs, anti-gp-tTG, and anti-h-tTG.
Results: Intestinal histology showed that 24 patients
had partial or total villous atrophy; in these patients the
diagnosis of CD was confirmed by follow-up. The
remaining 183 patients had villous/crypt ratios that were
within our laboratory’s reference values and were con-
sidered controls. Serum EmAs, anti-gp-tTG, and anti-h-
tTG were positive in all 24 CD patients; in the control
group, none were positive for serum EmAs, but 15 of 183
(8.2%) were positive for anti-gp-tTG, and 6 of 183 (3.3%)
were positive for anti-h-tTG. Sensitivity was 100% for
all assays, whereas specificity was 100% for the EmA,
92% for the anti-gp-tTG, and 97% for the anti-h-tTG
assay. The negative predictive value was 100% for all
assays; the positive predictive value was 100% for the
EmA, 80% [95% confidence interval (CI), 65–95%] for the
anti-h-tTG (P 0.03 vs EmA) and 60% (95% CI, 44–76%)
for the anti-gp-tTG assay (P  0.0002 vs EmA). Areas
(95% CIs) under the ROC curves were 0.987 (0.97–1.0) for
anti-h-tTG and 0.965 (0.94–0.99) for anti-gp-tTG. Most
of the patients testing false positive for anti-tTG had
Crohn disease or chronic liver disease.
Conclusions: Although both anti-tTG ELISAs showed
optimum sensitivity, their lack of specificity yielded
positive predictive values significantly lower than those
for the EmA assay.
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The recent introduction of an anti-tissue transglutaminase
(anti-tTG)4 assay in the diagnostic work-up of celiac
disease (CD) has offered a simpler means for evaluating
suspected CD and selecting patients to undergo intestinal
biopsy (1 ). Pretreatment of CD sera with tTG eliminated
the endomysial staining pattern in human umbilical cord,
suggesting that tTG could be the previously unknown
endomysium autoantigen (2, 3). Furthermore, reticulin,
endomysial, and jejunal antibodies detected transglut-
aminase in primate tissues, suggesting that these tissue
antibodies, and the anti-transglutaminase antibodies
themselves, could be identical (4 ). Consequently, it has
been suggested that the simpler and less expensive ELISA
developed to detect the presence of serum anti-tTG
autoantibodies could replace the immunofluorescence
technique traditionally used for the detection of anti-
endomysial antibodies (EmAs) (1–3, 5, 6). Recent reports,
however, have shown a high frequency of false-positive
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results with the most widely used anti-tTG ELISA, which
is based on guinea pig tTG (gp-tTG) as the antigen, in
patients with liver diseases (7, 8), and we found false-
positive results in patients with lymphoproliferative dis-
ease (9 ). Better results have been reported with a new
anti-tTG ELISA based on human tTG (h-tTG) as the
antigen (10 ). However, few studies have evaluated the
diagnostic accuracy of this new anti-h-tTG ELISA, and
almost all the studies on the anti-tTG assay have consid-
ered preselected groups of patients and not consecutive
individuals with suspected CD.
The aim of the present prospective study was to
compare the diagnostic accuracy of the EmA assay and
two commercially available anti-tTG ELISAs, one based
on gp-tTG and the other on h-tTG as antigen, in consec-
utive patients prospectively investigated for suspected
CD, all of whom underwent intestinal biopsies.
Patients and Methods
This study included 207 consecutive adult patients (99
males and 108 females; age range, 17–84 years; median, 42
years) who had undergone intestinal biopsies for sus-
pected CD between January 1999 and February 2000 at the
outpatient clinics of two different Divisions of Internal
Medicine and at a Surgery Department of the University
Hospital in Palermo. All patients included in the study
were followed as outpatients. The patients presented one
or more of the following symptoms: weight loss (86
cases), anemia (81 cases), chronic diarrhea (80 cases),
abdominal pain (71 cases), dyspepsia (65 cases), alternat-
ing bowel habits (61 cases), constipation (20 cases), pain in
the joints (2 cases), and dermatitis (2 cases). Patients who
had undergone previous serologic or histologic evalua-
tion for suspected CD were ineligible for the study.
At entry in the study, on the same day as the intestinal
biopsy sampling, a serum sample was taken from each
patient for IgA anti-tTG and anti-EmA assays. Between
January and December 1999, only the gp-tTG ELISA was
performed immediately, and all the sera were stored at
80 °C. After December 1999, the new anti-tTG ELISA,
based on h-tTG as the antigen, was commercially avail-
able, and this assay was performed on the stored sera of
the patients recruited from January to December 1999.
From January to April 2000, both the gp-tTG and the
h-tTG IgA ELISA were performed immediately on entry
to the study. Total immunoglobulin values (IgA, IgM, and
IgG) were also measured by ELISA.
The diagnosis of CD was based on evidence of clinical
symptoms and partial or total intestinal villous atrophy
on a gluten-containing diet, disappearance of the symp-
toms and normalization of the intestinal histology on a
gluten-free diet, and reappearance of the symptoms on
gluten challenge.
According to the individual clinical presentation and
laboratory data, the diagnostic work-up of the patients
may also have included abdominal ultrasonography
and/or computed tomography, colonoscopy, small intes-
tine barium examination, liver histology, a H2 breath test,
and duodenal fluid microbiological evaluation.
The protocol was approved by the Ethics Committee of
the University Hospital of Palermo, and informed consent
was obtained from the patients involved in the study.
serum anti-tTG IgA elisa using gp-tTG as antigen
The anti-gp-tTG assay was performed with a commercial
ELISA (Eu.tTG IgA; Eurospital) in accordance with the
method described by Troncone et al. (5 ), modified accord-
ing to Sulkanen et al. (3 ). The antigen used in the ELISA
was gp-tTG (cat. no. T5398; Sigma). Values were ex-
pressed as a percentage of the values obtained for positive
reference sera [obtained from untreated celiac patients
diagnosed according to the criteria of the European Soci-
ety of Paediatric Gastroenterology and Nutrition (11 ) and
which tested positive for EmAs in all cases]. Anti-tTG
values greater than the 95th percentile of a control group
including 100 healthy controls and negative for serum
EmAs were considered positive (7% of the reference
serum). The intraassay CV was 8.7% (n  15), and the
interassay CV was 10% (n  15).
serum anti-tTG IgA elisa using recombinant
h-tTG as antigen
The anti-h-tTG ELISA was performed in our laboratory on
serum samples from 60 patients immediately after blood
collection and on serum samples, from 147 patients, that
had been kept frozen at 80 °C. A control test performed
in our laboratory on 30 serum samples in which anti-tTG
antibodies were first assayed on fresh serum and then 8
months later after storage at 80 °C showed that storage
at 80 °C did not significantly alter the results obtained:
the mean value ( SD) was 5.23%  0.71% for fresh
samples and 4.92%  0.75% for frozen samples. The
interassay CV was 7.9%.
Serum IgA recombinant anti-h-tTG antibody concen-
trations were determined using a commercially available
assay (Eu.tTG IgA umana; Eurospital). The purity of the
recombinant protein was assessed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis. Recombinant
h-tTG antigen diluted in phosphate-buffered saline was
used to coat the wells; serum samples diluted 1:26 (20 L
of serum plus 500 mL of phosphate-buffered saline) in
phosphate-buffered saline containing 1 mL/L Tween 20
were incubated for 1 h at room temperature. The plates
were washed three times and subsequently incubated for
1 h at room temperature with horseradish peroxidase-
labeled sheep anti-human IgA. The excess conjugate was
removed by washing, and a chromogenic substrate was
added. The absorbance was read in a microplate reader at
450 nm. Results were expressed as a percentage of the
positive control serum. Normal values were taken as
7%, which represented a value  2 SD above the mean
of 850 healthy individuals. The intraassay CV for the IgA
h-tTG autoantibody ELISA was 2.2% (n  30), and the
interassay CV was 5.8% (n  30).
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serum IgA EmA assay
IgA-class EmA values were determined with a commer-
cially available indirect immunofluorescence method on
monkey esophagus (Anti-endomisio; Eurospital Pharma),
as described previously (12, 13).
intestinal biopsy and histology
Biopsy specimens were taken during gastroduodenos-
copy at the second duodenal portion. In all cases, at least
two biopsy specimens were obtained. In accordance with
our previous studies (12–14), specimens adequate in size
were immediately oriented with the aid of a stereomicro-
scope and subsequently embedded in paraffin. The slides
were stained with hematoxylin and eosin and graded by
conventional histology as (a) normal, (b) partial villous
atrophy, or (c) subtotal/total villous atrophy. In addition,
the villous/crypt ratio was evaluated (reference values in
our laboratory 2.5 for children, 3 for adults), and the
number of intraepithelial lymphocytes (IELs) per 100
villous epithelial cells was assessed as described by Fer-
guson and Murray (15 ); the upper limit of the reference
values in our laboratory is 30 IELs/100 epithelial cells.
In all cases, histologic analysis was performed by an
examiner unaware of the clinical condition of the patients
and of the laboratory test results.
statistical analysis
We followed standard criteria for methodologic studies
on the diagnostic accuracy of tests (16 ). The sensitivities
and specificities of the methods examined and their
positive and negative predictive values were calculated
by standard statistical methods (17 ). The Fisher exact test
was used to compare the different positive and negative
predictive values of the three assays. In addition, ROC
curves were plotted to show the discriminative ability of
the tests. The model plots sensitivity (the proportion of
CD patients attributed by the test to the CD group) vs 1 
specificity (the proportion of control patients attributed
by the tests to the CD group). The areas under the ROC
curves and their 95% confidence intervals were also
calculated using the nonparametric method described by
Hanley and McNeil (18 ), developed as a statistical pro-
gram.
Results
Intestinal histology showed that 24 patients (10 males and
14 females; age range, 18–80 years; median, 30 years) had
a partial (7 cases) or total (17 cases) villous atrophy. In
these patients, the diagnosis of CD was confirmed by a
positive response to the gluten-free diet, which produced
a complete disappearance of the symptoms within 2–15
weeks after the beginning of the diet and a normalization
of the intestinal histology after 11–14 months (mean, 12.5
months). In these patients. the IEL count in the intestinal
mucosa biopsies ranged from 52 to 79 (median, 66) at the
time of the first biopsy. No patients were lost during
follow-up, and at the time of the second biopsy, all
patients showed villous/crypt ratios 3 and the IEL
count ranged from 18 to 29 (median, 24). In all cases,
gluten challenge caused the reappearance of the symp-
toms/signs that had initially led to suspicion of CD. The
remaining 183 patients (89 males and 94 females; age
range, 17–84 years; median, 46 years) included in the
study had an intestinal histology characterized by a
villous/crypt ratio 3 and, consequently, were consid-
ered as controls to evaluate the specificity of the diagnos-
tic tests for CD. Table 1 shows the final diagnoses for these
patients.
None of the patients included in the study showed
serum IgA deficiency. Serum EmAs and anti-tTG antibod-
ies, assayed with both the gp-tTG and the h-tTG ELISA,
were positive in all 24 CD patients (Table 2). In the control
group (non-CD patients), none were positive for serum
EmAs, but 15 of 183 (8.2%) were positive for anti-gp-tTG
and 6 of 183 (3.3%) were positive for anti-h-tTG (Table 2).
In the 15 controls positive for anti-gp-tTG, values ranged
between 9% and 24%; in the controls positive by the
anti-h-tTG ELISA, values ranged between 8.5% and 28%.
These values were in the same range as the values
observed in the 24 CD patients with partial or total
mucosa atrophy (range of values, 8–31% for gp-tTG and
9–34% for h-tTG). After performing a cumulative analysis
of the data from patients and controls, we plotted the
ROC curves for anti-h-tTG and anti-gp-tTG; the areas
Table 1. Final diagnoses in 183 non-CD patients included
in the study (one or more diagnoses possible for
each patient).a
Diagnosis No. of cases
Irritable bowel syndrome 70
Esophagitis 45
Peptic erosions/ulcers (gastric or duodenal) 41
Crohn disease 15
Food intolerance/allergy 10
Chronic liver disease 6
Gastric cancer 2
Right colon cancer 2
Collagenous colitis 1
Intestinal bacterial overgrowth syndrome 1
Psoriasis 1
a Patients underwent the serologic assays for CD diagnoses and were
considered as controls to evaluate the specificities of the assays studied.
Table 2. Number of cases positive for serum EmAs,
anti-gp-tTG, and anti-h-tTG in 24 CD patients and in
183 non-CD patients (controls).
Serum EmAs Serum anti-gp-tTG Serum anti-h-tTG
CD patients, n 24/24 24/24 24/24
Controls, n 0/183 15/183 6/183
Sensitivity,a % 100 (96–100) 100 (96–100) 100 (96–100)
Specificity,a % 100 (99–100) 92 (88–96) 97 (92–100)
a Values in parentheses are 95% CIs.
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under curves were 0.987 [95% confidence interval (CI),
0.97–1.0] for anti-h-tTG and 0.965 (95% CI, 0.94–0.99) for
anti-gp-tTG.
The patients with false-positive anti-tTG ELISA results
based on guinea pig antigen included seven with Crohn
disease (diagnosis was confirmed by histologic examina-
tion of ileal/colon biopsies and positive barium x-ray of
ileum examination and/or colonoscopy), three with mul-
tiple food intolerance (intolerance to cow’s milk and its
derivatives, fish, tomato, chocolate, and/or orange, diag-
nosed by means of an elimination diet that documented
the disappearance of the symptoms and a subsequent
blind challenge that demonstrated the reappearance of the
symptoms), three with chronic hepatitis attributable to a
hepatitis virus C infection (with moderate/severe liver
histology damage), one patient with biopsy-confirmed
collagenous colitis, and one with psoriasis. False-positive
results with human tTG antigen all were in the set of those
positive in the anti-gp-tTG ELISA: two patients with ileal
Crohn disease, two with chronic hepatitis, one with
psoriasis, and one with collagenous colitis. Three false-
positive results were obtained on fresh sera and three on
samples stored at 80 °C. Further examinations per-
formed on these six patients showed that they did not
carry the DQ2 or DQ8 HLA haplotypes, which character-
ize CD patients, and were negative for serum anti-gliadin
antibodies.
Because all three assays had a sensitivity of 100%,
without any false-negative results, they all had a negative
predictive value of 100% (Table 3). In our series (CD
prevalence, 11.6%), the positive predictive value was
100% only for the EmA assay. The two anti-tTG assays
that we evaluated had lower positive predictive values.
The anti-tTG assay based on guinea pig antigen had a
positive predictive value of 60%, significantly lower than
that of the EmA assay (P  0.0002, Fisher test), whereas
the anti-tTG assay based on human recombinant antigen
had a positive predictive value of 80%, also significantly
lower than that of EmA assay (P  0.03).
Discussion
After Dieterich et al. (2 ) demonstrated that tTG was the
main (or the sole) autoantigen recognized by EmAs in CD
patients, the use of an ELISA based on tTG was proposed
and widely accepted for the diagnostic evaluation of
patients with suspected CD (1, 3, 5, 6, 19–22). Although
there is general agreement that anti-tTG antibodies have a
good diagnostic accuracy in CD diagnosis, it is notewor-
thy that almost all the studies published to date have
investigated anti-tTG in preselected groups of patients
with a known diagnosis (1, 3, 5, 6, 19–23); there has been
one prospective study on the clinical usefulness of a
serum anti-tTG assay in unselected patients with a clinical
suspicion of CD, but this included a limited number of
patients (24 ).
In the present study, we considered a wide group of
individuals referred to three different centers and fol-
lowed as outpatients for clinical symptoms and/or signs
compatible with a diagnosis of CD. We compared the
anti-tTG ELISAs with the anti-EmA assay, which can be
considered the “gold standard” in the serology of CD
(25 ). Although the three assays identified all the CD
patients, this cannot be considered a generally reproduc-
ible result because we had no patients with a serum IgA
deficiency, a condition more common in CD than in the
general population, which limits the performance of the
serologic tests for CD based on IgA antibody determina-
tions.
The positive predictive value of the anti-gp-tTG assay
(60%) is too low to warrant subjecting a patient to
intestinal biopsy for suspected CD. This relatively low
positive predictive value of anti-gp-tTG, however, cannot
be considered completely unexpected. In fact, we ob-
tained false-positive results for seven patients with Crohn
disease, a condition in which a high prevalence of anti-
tTG antibodies has been reported previously (26 ), and in
four patients with intestinal disease characterized by
moderate/severe mucosal inflammation (three patients
with multiple food intolerance and one patient with
biopsy-confirmed collagenous colitis). Three other pa-
tients who were false positive for anti-gp-tTG antibodies
had chronic hepatitis attributable to a hepatitis virus C
infection, a liver disease in which we have previously
demonstrated a 14% frequency of false-positive results (27).
All six false positives in the anti-h-tTG assay were also
positive in the anti-gp-tTG assay. Although we had no
doubts about excluding a CD diagnosis in the two pa-
tients with Crohn disease and in the two with chronic
liver disease, both collagenous colitis (28 ) and psoriasis
(29 ) have been reported to be associated with CD. How-
ever, the intestinal biopsies of these two patients, per-
formed at the second portion of the duodenum, did not
show alterations of the villi or crypts (ratio of villi to
crypts 3), and serum IgG and IgA anti-gliadin antibod-
ies were negative. Moreover, they did not have the
classical HLA DQ2 or DQ8 alleles, which are typical of CD
patients. The low positive predictive values of the anti-
tTG assays will be even lower at lower prevalences of CD,
such as those commonly reported in studies of consecu-
tive patients with dyspepsia (30, 31).
The false-positive results observed in our study could
arise from impurities in the gp-tTG for the ELISA system
Table 3. Positive and negative predictive values (95% CIs)
for the anti-EmA assay, the anti-gp-tTG ELISA, and the








100 (96–100) 60 (44–76) 80 (65–95)
Negative predictive
value, %
100 (99–100) 100 (99–100) 100 (99–100)
a Values were calculated according to the prevalence of 11.6% of CD observed
in this study group.
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based on this antigen, as we have previously suggested in
other studies (9, 27). For the false-positive results ob-
tained with the specific recombinant h-tTG in the ELISA
system, the hypothesis of protein impurities in the tTG
preparation can also be considered, but we do not exclude
the possibility that high serum concentrations of anti-tTG
antibodies were really present in some “controls”. Immu-
noblot or immunoprecipitation studies with false-positive
sera are needed to determine whether the reactive band is
really tTG.
In conclusion, the EmA assay has a higher positive
predictive value than the anti-tTG assays in CD diagnosis.
On this basis, the simpler anti-h-tTG ELISA could be
suggested as a first-step examination, with positive re-
sults to be confirmed by the EmA assay. We suggest that
discordant anti-tTG/EmA results merit further evalua-
tion, e.g., by means of HLA DQ determination.
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